Les immunoconjugués en oncologie

Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor

(2018) Glenwood D. Goss et al.   CANCER

Doxorubicin conjugated with a trastuzumab epitope and an MMP-2 sensitive peptide linker for the treatment of HER2-positive breast cancer

(2018) Yiwen You et al.   DRUG DELIVERY

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial

(2018) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of cathepsin B-sensitive triggers and hydrophilic linkers on in vitro efficacy of novel site-specific antibody–drug conjugates

(2018) Francesca Bryden et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro

(2018) Nicolas Aubrey et al.   BIOCONJUGATE CHEMISTRY

Phase 1 dose-escalation study of brentuximab-vedotin combined with dexamethasone, high-dose cytarabine and cisplatin, as salvage treatment in relapsed/refractory classical Hodgkin lymphoma: the Transplant BRaVE study

(2018) Anton Hagenbeek et al.   HAEMATOLOGICA

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

(2018) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy

(2017) Nicolas Joubert et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Engineering humanized antibody framework sequences for optimal site-specific conjugation of cytotoxins

(2017) Jared L. Spidel et al.   mAbs

Antibody–Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments

(2017) Aiko Nagayama et al.   Targeted Oncology

From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs)

(2016) Julia Mantaj et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy

(2016) John Y. Li et al.   CANCER CELL

Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models

(2016) P. M. Challita-Eid et al.   CANCER RESEARCH

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

(2016) Y. Ogitani et al.   CLINICAL CANCER RESEARCH

New developments for antibody-drug conjugate-based therapeutic approaches

(2016) Bart ECG de Goeij et al.   CURRENT OPINION IN IMMUNOLOGY

Prospects and progress of antibody-drug conjugates in solid tumor therapies

(2016) Serengulam V. Govindan et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates

(2016) Alain Beck et al.   Expert Review of Proteomics

Increment in Drug Loading on an Antibody–Drug Conjugate Increases Its Binding to the Human Neonatal Fc Receptor in Vitro

(2016) Guillaume Brachet et al.   MOLECULAR PHARMACEUTICS

Processes for Constructing Homogeneous Antibody Drug Conjugates

(2016) David Y. Jackson   ORGANIC PROCESS RESEARCH & DEVELOPMENT

Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models

(2016) Jose F. Ponte et al.   NEOPLASIA

Development of Anilino-Maytansinoid ADCs that Efficiently Release Cytotoxic Metabolites in Cancer Cells and Induce High Levels of Bystander Killing

(2015) Wayne C. Widdison et al.   BIOCONJUGATE CHEMISTRY

Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development

(2015) Paresh Agarwal et al.   BIOCONJUGATE CHEMISTRY

A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs

(2015) S.-F. Yu et al.   CLINICAL CANCER RESEARCH

Emerging formats for next-generation antibody drug conjugates

(2015) Mahendra P Deonarain et al.   Expert Opinion on Drug Discovery

Antibody–Drug Conjugates and Small Molecule–Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents

(2015) Giulio Casi et al.   JOURNAL OF MEDICINAL CHEMISTRY

Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates

(2015) R. Gebleux et al.   MOLECULAR CANCER THERAPEUTICS

Antibody–Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs

(2015) Christopher R. Behrens et al.   MOLECULAR PHARMACEUTICS

Noninternalizing Targeted Cytotoxics for Cancer Therapy

(2015) Giulio Casi et al.   MOLECULAR PHARMACEUTICS

Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985

(2015) Ronald C. Elgersma et al.   MOLECULAR PHARMACEUTICS

Combination cancer immunotherapy and new immunomodulatory targets

(2015) Kathleen M. Mahoney et al.   NATURE REVIEWS DRUG DISCOVERY

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

(2015) David M. Goldenberg et al.   Oncotarget

Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy

(2014) Ravi V. J. Chari et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Bridging Disulfides for Stable and Defined Antibody Drug Conjugates

(2014) George Badescu et al.   BIOCONJUGATE CHEMISTRY

Site-Specific Labeling of Cysteine-Tagged Camelid Single-Domain Antibody-Fragments for Use in Molecular Imaging

(2014) Sam Massa et al.   BIOCONJUGATE CHEMISTRY

Versatility of Microbial Transglutaminase

(2014) Pavel Strop   BIOCONJUGATE CHEMISTRY

Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)

(2014) H. Uppal et al.   CLINICAL CANCER RESEARCH

Next generation maleimides enable the controlled assembly of antibody–drug conjugates via native disulfide bond bridging

(2014) Felix F. Schumacher et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

(2013) M. S. Kung Sutherland et al.   BLOOD

Site-specific antibody drug conjugates for cancer therapy

(2013) Siler Panowski et al.   mAbs

Risks and untoward toxicities of antibody-based immunoconjugates

(2012) Dana Litvak-Greenfeld et al.   ADVANCED DRUG DELIVERY REVIEWS

Cancer stromal targeting (CAST) therapy

(2011) Yasuhiro Matsumura   ADVANCED DRUG DELIVERY REVIEWS

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

(2008) Jagath R Junutula et al.   NATURE BIOTECHNOLOGY